Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia.
School of Health Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia.
Life Sci. 2022 Sep 15;305:120734. doi: 10.1016/j.lfs.2022.120734. Epub 2022 Jun 24.
The advances in the development of drugs and vaccines for major infectious diseases of tuberculosis (TB), malaria and HIV represent some of the most significant milestones in their therapeutic strategies. Yet, current drugs and vaccines display limitations such as drug resistance and low efficacy level. In recent years, new emerging and advanced nano-technology carrier liposomes have been widely studied towards producing drugs and vaccines capable of targeting infectious diseases. Liposomes portrayed biocompatible and biodegradable properties with versatile flexibility, characteristics that are advantageous for a good targeting at the site of action. The success of liposomes has renewed interest in the research and development of liposomal drugs and vaccines shifting the paradigm in infectious diseases treatment. This review focuses on the limitations of current therapeutic drugs and vaccines, the knowledge of liposomes in terms of their classifications and advantages, and a review of the application of liposomes in the treatment of TB, malaria, and HIV infection.
在结核病(TB)、疟疾和艾滋病等主要传染病药物和疫苗的开发方面取得的进展,代表了其治疗策略中一些最重要的里程碑。然而,目前的药物和疫苗存在耐药性和低疗效等局限性。近年来,新出现的先进纳米技术载体脂质体在研究生产能够针对传染病的药物和疫苗方面得到了广泛的研究。脂质体具有生物相容性和可生物降解性,具有多功能的灵活性,这些特性有利于在作用部位进行靶向治疗。脂质体的成功重新激发了人们对脂质体药物和疫苗研发的兴趣,改变了传染病治疗的模式。本文重点介绍了目前治疗药物和疫苗的局限性,脂质体在分类和优势方面的知识,以及脂质体在结核病、疟疾和艾滋病感染治疗中的应用综述。